Skip to main content
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2016 Nov 14;2016:7267956. doi: 10.1155/2016/7267956

Corrigendum to “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease”

Bryan Phillips-Farfán 1, Karla Carvajal 1, Edgar Alejandro Medina-Torres 2, Sara Elva Espinosa-Padilla 2, Gemma Fabrias 3, Luz Camacho 1,*
PMCID: PMC5124652  PMID: 27965522

In the article titled “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease” [1], reference [28] was incorrectly added as follows:

  • [28]

    “Y. Chen, S.-C. Xu, and R.-D. Duan, ‘Mevalonate inhibits acid sphingomyelinase activity, increases sphingomyelin levels and inhibits cell proliferation of HepG2 and Caco-2 cells,' Lipids in Health and Disease, vol. 14, no. 1, article 130, 2015.”

It should be replaced with the following reference:

  • [28]

    “Chen Y, et al. Enhanced colonic tumorigenesis in alkaline sphingomyelinase (NPP7) knockout mice. Mol Cancer Ther, 14:1, 259-67, 2015.”

References

  • 1.Bryan P.-F., Karla C., Edgar Alejandro M.-T., Sara Elva E.-P., Gemma F., Luz C. Sphingolipids as mediators in the crosstalk between microbiota and intestinal cells: implications for inflammatory bowel disease. Mediators of Inflammation. 2016;2016:11. doi: 10.1155/2016/9890141.9890141 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES